Savant Capital LLC Sells 5,487 Shares of PTC Therapeutics, Inc. $PTCT

Savant Capital LLC lessened its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 39.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,281 shares of the biopharmaceutical company’s stock after selling 5,487 shares during the period. Savant Capital LLC’s holdings in PTC Therapeutics were worth $404,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. AlphaQuest LLC lifted its holdings in shares of PTC Therapeutics by 337.7% in the 2nd quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company’s stock worth $386,000 after buying an additional 6,102 shares during the period. Sector Gamma AS raised its holdings in shares of PTC Therapeutics by 41.4% in the first quarter. Sector Gamma AS now owns 92,250 shares of the biopharmaceutical company’s stock valued at $4,701,000 after acquiring an additional 27,000 shares in the last quarter. Deutsche Bank AG lifted its stake in PTC Therapeutics by 262.1% in the first quarter. Deutsche Bank AG now owns 341,724 shares of the biopharmaceutical company’s stock worth $17,414,000 after acquiring an additional 247,346 shares during the period. Cerity Partners LLC purchased a new stake in PTC Therapeutics in the first quarter worth about $641,000. Finally, Nuveen LLC bought a new position in PTC Therapeutics during the 1st quarter worth about $51,427,000.

PTC Therapeutics Price Performance

Shares of NASDAQ:PTCT opened at $75.30 on Monday. The business’s 50-day moving average is $65.29 and its 200 day moving average is $54.53. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $76.80. The firm has a market capitalization of $6.05 billion, a P/E ratio of 10.80 and a beta of 0.60.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The business had revenue of $211.01 million for the quarter, compared to analyst estimates of $177.42 million. During the same quarter in the previous year, the firm earned ($1.39) earnings per share. The company’s revenue was up 7.2% on a year-over-year basis. PTC Therapeutics has set its FY 2025 guidance at EPS. On average, analysts expect that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PTCT. Robert W. Baird set a $70.00 price target on shares of PTC Therapeutics in a report on Friday, August 8th. The Goldman Sachs Group lifted their price target on PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of PTC Therapeutics in a research report on Thursday. Royal Bank Of Canada increased their price target on shares of PTC Therapeutics from $70.00 to $82.00 and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Finally, Truist Financial lifted their price objective on shares of PTC Therapeutics from $80.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, July 29th. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $75.40.

Insider Buying and Selling at PTC Therapeutics

In related news, Director Allan Steven Jacobson sold 12,000 shares of the company’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $65.00, for a total value of $780,000.00. Following the transaction, the director directly owned 17,451 shares of the company’s stock, valued at $1,134,315. This represents a 40.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Pauwels sold 39,850 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $56.92, for a total value of $2,268,262.00. Following the completion of the transaction, the insider owned 72,912 shares of the company’s stock, valued at $4,150,151.04. This trade represents a 35.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 261,995 shares of company stock worth $16,547,129 in the last three months. 5.50% of the stock is owned by company insiders.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.